Search results
Results from the WOW.Com Content Network
Aromatase (EC 1.14.14.14), also called estrogen synthetase or estrogen synthase, is an enzyme responsible for a key step in the biosynthesis of estrogens. It is CYP19A1 , a member of the cytochrome P450 superfamily, which are monooxygenases that catalyze many reactions involved in steroidogenesis .
Aromatase excess syndrome (AES or AEXS) is a rarely diagnosed genetic and endocrine syndrome which is characterized by an overexpression of aromatase, the enzyme responsible for the biosynthesis of the estrogen sex hormones from the androgens, in turn resulting in excessive levels of circulating estrogens and, accordingly, symptoms of hyperestrogenism.
The biosynthesis of phytoalexins, antimicrobial compounds produced by some plants, involves the P450 enzymes CYP79B2, CYP79B3, CYP71A12, CYP71A13, and CYP71B15. The first step of camalexin biosynthesis produces indole-3-acetaldoxime (IAOx) from tryptophan and is catalyzed by either CYP79B2 or CYP79B3.
1,4,6-Androstatriene-3,17-dione (ATD) is a potent irreversible aromatase inhibitor that inhibits estrogen biosynthesis by permanently binding and inactivating aromatase in adipose and peripheral tissue. [1] It is used to control estrogen synthesis. [2]
Aromatase deficiency is a rare condition characterized by extremely low levels or complete absence of the enzyme aromatase activity in the body. [2] It is an autosomal recessive disease resulting from various mutations of gene CYP19 (P450arom) which can lead to ambiguous genitalia and delayed puberty in females, continued linear growth into adulthood and osteoporosis in males and virilization ...
The pathway of estrogen biosynthesis in extragonadal tissues is different. These tissues are not able to synthesize C19 steroids, and therefore depend on C19 supplies from other tissues [99] and the level of aromatase. [100] In females, synthesis of estrogens starts in theca interna cells in the ovary, by the synthesis of androstenedione from ...
4-AT is a potent irreversible aromatase inhibitor that inhibits estrogen biosynthesis by permanently binding and inactivating aromatase in adipose and peripheral tissue. [4] [5] [6] Aromatase is responsible for the conversion of testosterone to estradiol.
Induction of apoptosis by 2-meOE 2 may be p53 dependent or independent. 2-meOE 2 has also been found to inhibit aromatase activity, thereby lowering the in situ synthesis of E 2 in cancer tissue. [4] 2-meOE 2 has a higher binding affinity for sex hormone-binding globulin (SHBG) than E 2 and 2-OH-E 2 and has no affinity for the estrogen receptor.